• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>GlaxoSmithKline

GlaxoSmithKline

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Novartis Begins to See Benefits of Overhaul -- 2nd Update

    Novartis Begins to See Benefits of Overhaul -- 2nd Update

  2. Novartis Begins to See Benefits of Overhaul -- Update

    Novartis Begins to See Benefits of Overhaul -- Update

  3. UPDATE: U.S. Firms Urge China to Improve Conditions

    UPDATE: U.S. Firms Urge China to Improve Conditions

  4. U.S. Firms Want China to Improve Business Conditions

    U.S. Firms Want China to Improve Business Conditions

  5. Research and Markets: Kidney Cancer Drugs (Afinitor, Avastin, Inlyta, Nexavar, Proleukin, Sutent, Torisel, Votrient) Market - Global Industry Analysis 2014-2020

    Research and Markets: Kidney Cancer Drugs (Afinitor, Avastin, Inlyta, Nexavar, Proleukin, Sutent, Torisel, Votrient) Market - Global Industry Analysis 2014-2020

  6. Reality-TV Star Blows Whistle Again

    Reality-TV Star Blows Whistle Again

  7. Agenus to Report First Quarter 2015 Financial Results on April 23, 2015; Conference Call to Follow

    Agenus to Report First Quarter 2015 Financial Results on April 23, 2015; Conference Call to Follow

  8. Squabbles Over Testing Methods Hamper Search for Ebola Vaccine

    Squabbles Over Testing Methods Hamper Search for Ebola Vaccine

  9. At Bayer, A Dose Of US Risk-Taking

    At Bayer, A Dose Of US Risk-Taking

  10. Bayer's CEO Injects a Dose of U.S. Risk-Taking

    Bayer's CEO Injects a Dose of U.S. Risk-Taking

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.